Clinigen Group plc Total Voting Rights (7014D)
28 June 2019 - 8:00PM
UK Regulatory
TIDMCLIN
RNS Number : 7014D
Clinigen Group plc
28 June 2019
28 June 2019
Clinigen Group plc
("Clinigen" or the "Group")
Total Voting Rights and Capital
In conformity with Rule 5.6.1 of the Disclosure Guidance and
Transparency Rules, the Group notifies the market that as at 28
June 2019, Clinigen's issued share capital consists of 132,479,167
ordinary shares of 0.1 pence each with voting rights. No shares are
held in Treasury.
The above figure of 132,479,167 may be used by shareholders as
the denominator to determine if they are required to notify their
interests in, or a change to their interests in, the Group under
the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Matt Parrish, Head of Investor Relations
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Black / Freddie Barnfield / Freddie
Naylor-Leyland
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Rozi Morris / Deborah
Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific. In October 2018, the Group
acquired CSM, a specialist provider of packaging, labelling,
warehousing and distribution services, with sites in the US and
Europe, and iQone, a specialist pharmaceutical company in
Switzerland.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRDMGZVFNGGLZM
(END) Dow Jones Newswires
June 28, 2019 06:00 ET (10:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024
